Replies to post #808 on Theralink Technologies Inc (THER)

[Prince Goro]

Did you know that in the phase 1 data of $OBMP Proscavax, none of the 15 patients who have had at least one vaccine have had a dose limiting adverse event (DLAE) http://oncbiomune.com/2016/08/08/latest-data-from-phase-1-trial-of-proscavax-for-prostate-cancer-reinforces-safety-and-benefit-of-novel-cancer-vaccine/